Mirtazapin Viatris (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonizing postsynaptic 5‑HT2 and 5‑HT3 receptors while strongly inhibiting histamine H1 receptors. This combined effect enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant activity.

The dosage of Mirtazapin Viatris is individualized. A qualified prescriber determines the appropriate dose based on the patient’s clinical condition, response to therapy, and tolerability. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for mirtazapine in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers must evaluate each case carefully.

To order Mirtazapin Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Viatris (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors, as well as strong H1 antagonism. This profile often results in pronounced sedation and increased appetite, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about these effects.

Mirtazapin Viatris should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture. It does not require refrigeration. Keep the product out of reach of children and avoid exposure to direct sunlight.

Mirtazapin Viatris is administered orally, typically as a tablet taken once daily in the evening. The exact timing and any special instructions, such as taking with or without food, should follow the prescribing clinician’s guidance.

Serious risks include the potential for agranulocytosis or severe neutropenia, rare hypersensitivity reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, especially during early treatment. Patients should be monitored closely for any signs of infection, rash, or changes in mood.

Mirtazapin Viatris is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients. It should also be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with a history of severe hepatic impairment without appropriate medical supervision.